JW Pharmaceutical Corp (001065) — Capital Reinvestment Ratio

Latest as of September 2025: 0.21x

JW Pharmaceutical Corp (001065) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩46.92 Billion) in capital expenditures (₩9.80 Billion). See JW Pharmaceutical Corp free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.21x
Capex / Operating Cash Flow

Operating Cash Flow

₩46.92 Billion
KRW

Capital Expenditures

₩9.80 Billion
KRW

Data as of

Sep 2025
Most recent filing

JW Pharmaceutical Corp Capital Reinvestment Ratio (2014–2024)

This chart tracks JW Pharmaceutical Corp's Capital Reinvestment Ratio across 10 annual periods.

Annual Capital Reinvestment Ratio for JW Pharmaceutical Corp (2014–2024)

Year-by-year Capital Reinvestment Ratio for JW Pharmaceutical Corp from 2014 to 2024. For live market cap and broader valuation context, see JW Pharmaceutical Corp stock valuation.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2024 0.35x ₩79.39 Billion ₩28.14 Billion ▼ -24.1%
2023 0.47x ₩87.16 Billion ₩40.71 Billion ▲ +167.3%
2022 0.17x ₩56.76 Billion ₩9.92 Billion ▼ -57.6%
2021 0.41x ₩18.12 Billion ₩7.47 Billion ▲ +109.7%
2020 0.20x ₩63.05 Billion ₩12.39 Billion ▲ +17.5%
2019 0.17x ₩55.53 Billion ₩9.28 Billion ▲ +0.9%
2018 0.17x ₩52.11 Billion ₩8.64 Billion ▼ -26.1%
2017 0.22x ₩33.45 Billion ₩7.50 Billion ▼ -84.9%
2016 1.49x ₩6.74 Billion ₩10.02 Billion ▲ +56.2%
2014 0.95x ₩7.28 Billion ₩6.93 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow